Arca biopharma, inc. (ABIO)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13Jun'13Sep'12Jun'12Sep'11Jun'11Jun'10
Costs and expenses:
Research and development

365

384

347

440

662

625

740

1,154

1,720

2,834

3,488

4,508

3,246

3,121

3,720

2,913

2,594

1,893

1,716

1,747

1,707

1,582

1,335

1,400

1,308

714

246

156

322

533

497

700

General and administrative

975

894

900

1,068

1,119

902

922

1,002

1,053

1,463

987

1,051

1,135

1,171

992

1,028

1,074

1,282

1,101

972

1,037

1,030

950

1,006

1,082

-

-

-

-

-

-

-

General and administrative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,011

952

772

823

1,288

1,207

1,569

Merger transaction costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

Restructuring expense, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

Loss on impairment of in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

Total costs and expenses

1,340

1,278

1,247

1,508

1,781

1,527

1,662

2,156

2,773

4,297

4,475

5,559

4,381

4,292

4,712

3,941

3,668

3,175

2,817

2,719

2,744

-

2,285

-

-

1,725

1,198

928

1,145

1,821

1,704

2,269

Total costs and expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,406

2,390

-

-

-

-

-

-

-

Loss from operations

-1,340

-1,278

-1,247

-1,508

-1,781

-1,527

-1,662

-2,156

-2,773

-4,297

-4,475

-5,559

-4,381

-4,292

-4,712

-3,941

-3,668

-3,175

-2,817

-2,719

-2,744

-2,612

-2,285

-2,406

-2,390

-1,725

-1,198

-928

-1,145

-1,821

-1,704

-2,269

Gain on assignment of patent rights

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2,000

-

Gain on bargain purchase

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

Interest and other income

24

36

50

48

38

38

40

43

41

39

44

39

45

48

53

47

21

7

4

2

1

1

2

2

2

2

1

2

1

1

0

-

Interest expense

4

0

1

3

3

0

2

3

3

0

2

2

2

-

-

-

-

0

1

2

1

0

1

1

1

-

-

-

-

-

-

-

Loss before income taxes

-1,320

-1,242

-1,198

-1,463

-1,746

-1,489

-1,624

-2,116

-2,735

-

-4,433

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest and other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

Interest and other expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

1

2

2

2

2

Loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,723

-1,199

-927

-1,146

-1,822

294

-2,270

Income tax benefit

-

-16

-42

-27

-82

-

-31

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

-

Net loss

-1,320

-1,226

-1,156

-1,436

-1,664

-1,489

-1,593

-2,116

-2,735

-4,197

-4,433

-5,522

-4,338

-4,244

-4,659

-3,894

-3,647

-3,168

-2,814

-2,719

-2,744

-2,611

-2,284

-2,405

-2,389

-1,723

-1,199

-927

-1,146

-1,822

294

-2,270

Change in unrealized loss on marketable securities

-

-

-

-

-

0

0

0

2

1

2

4

10

-13

-19

7

6

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-

-

-1,156

-1,436

-

-1,489

-1,593

-2,116

-2,733

-4,196

-4,431

-5,518

-4,328

-4,257

-4,678

-3,887

-3,641

-3,168

-2,814

-2,719

-2,744

-

-

-

-

-

-

-

-

-

-

-

Net loss per share:
Less: Accretion of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

Less: Deemed preferred stock dividend

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,026

0

0

0

0

-

Net loss available to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,723

-3,225

-927

-1,146

-1,822

294

-2,270

Basic and diluted

-0.83

-0.39

-0.76

-1.14

-1.86

-1.90

-2.06

-2.74

-3.61

-0.31

-0.39

-0.59

-0.48

-0.47

-0.51

-0.43

-0.40

0.09

-0.31

-0.69

-0.91

-2.31

-0.76

-0.11

-0.13

-0.16

-0.65

-0.07

-

-0.17

-

-

Weighted average shares outstanding:
Basic and diluted

1,594

1,603

1,521

1,263

895

773

773

773

756

11,803

11,502

9,324

9,094

9,082

9,068

9,065

9,053

9,147

9,034

3,951

3,023

-31,084

3,004

21,009

18,785

10,832

4,944

13,702

-

10,499

-

-

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.09

-

0.03

-0.26

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.09

-

0.03

-0.26

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12,166

-

10,129

8,732

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12,166

-

10,250

8,732